Revvity, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$28Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
35clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Anti-Bp180-Nc16a-4x Elisa (Igg) $3,000 associated (2023-2025)
- Ids-Isys Ostase Bap $3,000 associated (2023-2025)
- Ids-Isys Ctx-I (Crosslaps) $3,000 associated (2023-2025)
- Ids-Isys Intact Pth $3,000 associated (2023-2025)
- Anti-Desmoglein 1 Elisa (Igg) $3,000 associated (2023-2025)
- Anti-Bp230-Cf Elisa (Igg) $3,000 associated (2023-2025)
- T-Spot.Tb50 $3,000 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Victoria Odesina | New Britain, CT | Psychiatric/Mental Health (Nurse Practitioner) | $6,421.01 |
| Matthew Saidel | Avon, CT | Obstetrics & Gynecology | $4,626.56 |
| Animesh Sinha | Williamsville, NY | Dermatology | $3,000.00 |
| Sandeep Dhindsa | Saint Louis, MO | Endocrinology, Diabetes & Metabolism | $3,000.00 |
| Elizabeth Talbot | Lebanon, NH | Infectious Disease | $3,000.00 |
| Juzar Ali | New Orleans, LA | Pulmonary Disease | $3,000.00 |
| Jennifer Kelly | South Burlington, VT | Endocrinology, Diabetes & Metabolism | $3,000.00 |
| Rachel Cooper-Mercado | Sebring, FL | Obstetrics & Gynecology | $181.01 |
| Lea Mahoney | Richmond, VA | Obstetrics & Gynecology | $146.43 |
| Katherine Bryant | Fishersville, VA | Obstetrics & Gynecology | $122.86 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.